Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.72 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11180415 | 0.89 | L3MBTL1 (0.68) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL18177832 | 0.84 | TSHR (0.69) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7733701 | 0.84 | L3MBTL1 (1.00) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL13134415 | 0.81 | MDM2 (0.52) | L3MBTL1MDM2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14571967 | 0.81 | MDM2 (0.61) | L3MBTL1MDM2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4366118 | 0.79 | MDM2 (0.59) | L3MBTL1MDM2MAPTNPC1RAB9A | |
| SCHEMBL2862896 | 0.79 | MDM2 (0.59) | L3MBTL1MDM2MAPTALDH1A1CYP1A2 | |
| SCHEMBL16702198 | 0.79 | L3MBTL1 (0.59) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL83110 | 0.78 | L3MBTL1 (0.78) | L3MBTL1MAPTALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL20221228 | 0.78 | MDM2 (0.48) | L3MBTL1MDM2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| CN-1745064-A | Pyridines for the treatment of damaged mammalian neural tissue | PURDUE RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | CN | claimed |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | InventisBio Co., Ltd. (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-119954772-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954775-A | Heteroaryl compounds, methods of making and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240140929-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO LLC | 2024-05-02 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4267565-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| EP-0475352-B1 | 3-(1H-Indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5166163-A | (4-amino-3-pyridinyl)-2 -fluorophenylmethanone hydrazone and derivatives as chemical intermediates for 3-(1H-indazol-3-yl) 4-pyridinamines | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0475352-A1 | 3-(1H-Indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-03-18 | — | — | EP | disclosed |
| EP-0471297-A1 | 3-(1,2-Benzisoxazol-3-yl)-4-pyridinamines and derivatives | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-02-19 | — | — | EP | disclosed |
| US-5055476-A | Analgesic; antiinflammatory agents for skin treatment; cholinergic agents in treament of Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-10-08 | — | — | US | disclosed |
| US-5051430-A | Analgesics and antiinflammatory agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0435222-A2 | Aminopyridinylmethanols and aminomethylpyridinamines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4971964-A | INHIBITORS OF THROMBOXANE SYNTHASE, CARDIOVASCULAR DISORDERS, ANTIINFLAMMATORU AGENTS, CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0347831-A2 | Pyridine derivatives and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | L3MBTL1 4350/4885MDM2 1388/4885MAPT 717/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | L3MBTL1 1142/4885MDM2 3352/4885MAPT 2827/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | L3MBTL1 2216/4885MDM2 3943/4885MAPT 3857/4885 |
| US-20240140929-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | TYK2, IL2, JAK2 | L3MBTL1 4762/4885MDM2 1552/4885MAPT 1444/4885 |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | TYK2, IL2, IL23R | L3MBTL1 4747/4885MDM2 1142/4885MAPT 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.